A life science research tools manufacturer based in Western Europe with offices worldwide is interested in partnering with companies developing cutting-edge products that are a strategic fit for the firm’s portfolio. The firm is looking for novel product line addition opportunities globally and possible investments in early stage companies located in North America or Europe who are pursuing technology-leading approaches in the firm’s selected application fields.
The firm is focused on investing in companies that are developing products used in research labs, including consumables, bioprocess and lab automation equipment, and digital tools used by research scientists. The firm generally invests in companies with products that are at the commercial stage. The firm is targeting emerging, non-public companies who are pursuing applications in the areas of Molecular Biology, AI/Digital and Cell Biology.
The firm is flexible about partnering structure and open to a range of approaches including licensing, co-development, equity investments and acquisitions. The firm is a first-for-the-company, corporate venture fund with a charter towards select, new business line-directed equity investments.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
RESI Bundle Extended to Tomorrow
By Caitlin Dolegowski, Marketing Specialist, LSN
The end of the year is a critical time for early-stage fundraising. It is imperative for founders to end the year on a strong note and be ready to continue connections and building new relationships into the new year. To aid in this endeavor, Life Science Nation (LSN) is offering an extended bundle for Digital RESI, November 15-16 and RESI JPM San Francisco, January 10-12.
Digital RESI is LSN’s virtual event, featuring two days of dedicated partnering. This event provides early-stage entrepreneurs with the opportunity to connect with capital and licensing partners who are a fit for their product and stage of development before the end of the year. If Digital RESI November is a dress rehearsal, then consider RESI JPM San Francisco opening night. RESI JPM San Francisco is a hybrid event taking place during the JPM healthcare week – the life science industry’s biggest event of the year. The hybrid format features a day of in-person partnering, live investor panels, educational workshops, and the Innovator’s Pitch Challenge (applications now open!) on January 10, followed by two days of dedicated virtual partnering to allow attendees to take advantage of the RESI platform while also experiencing all the events taking place simultaneously.
The bundle package extended deadline is tomorrow, October 28. Sign up to take advantage of these deals and save $1,000 to ensure a strong end to the 2022 fundraising season and a promising start to the next one.
Voices of the 2022 Innovator’s Pitch Challenge
By Rory McCann, Director of Marketing & Conference Producer, LSN
Applications are now open for the first 2023 Innovator’s Pitch Challenge (IPC) taking place in-person at RESI JPM San Francisco on January 10! The IPC is Life Science Nation (LSN)’s pitch competition dedicated to putting talented founders and promising tech in front of a live panel of investors who are a fit for their product and stage of development. The IPC is a popular mainstay at both digital and hybrid RESI events, and RESI JPM San Francisco will be no exception!
Learn more about the IPC and hear from 2022 winners. The following interviews were with companies and founders who have found value in the process and connections associated with their pitch experience with RESI. Applications close November 30, so submit your application today!
- Bold Therapeutics (2nd Place, March 2022)
- Prolifagen Therapeutics (3rd Place, January 2022)
- Amplified Sciences (Finalist, September 2022 / 1st Place, January 2022)
LSN at The MedTech Conference
By Alexander Vassallo, Manager of Business Development West Coast (US), Entrepreneurial Education Lead, LSN
Life Science Nation (LSN) attended The MedTech Conference at the Boston Convention & Exhibition Center this week alongside some of the industry’s most innovative technology assets and professional development services. Located at Booth #910 and led by Dennis Ford, Founder and CEO of LSN, this was an exciting opportunity to connect with global players in the medtech industry and begin to build lasting relationships for years to come.
Featuring an array of well-delivered pitches by fundraising executives and interesting panels covering important industry topics, The MedTech Conference powered by AdvaMed provided ample opportunity for networking and establishing the dialogue with key players in the global device sector. Representatives from over 30 countries attended the conference and it was an excellent opportunity for LSN to connect with international groups looking to propagate the growth of their regions’ medical device sectors.
A highlight was connecting with MTPConnect, an Australian-based biotechnology and medical device growth center, which served to further LSN’s relationship with the Australian life sciences community – a relationship that was cemented earlier this year with the engagement of twelve medtech startups from Brisbane Economic Development Agency (BEDA) in LSN’s education curriculum and RESI JPM San Francisco, January 10-12, 2023.
As we approach 2023, maintaining established industry relationships and building new ones through leading partnering events like The MedTech Conference and RESI are essential to continue the growth propagation of the life sciences sector. The opportunity at the Boston Convention & Exhibition Center this week was certainly a rewarding one for all involved. To learn more about RESI and take advantage of exclusive bundles, visit our website and we hope to see you virtually at Digital RESI, November 15-16 and via our hybrid format at RESI JPM San Francisco, January 10-12!
Hot Investor Mandate: Investment Firm and Incubator With US HQ Invests $2-10M in Early & Late-Stage Financings, Most Interested in Therapeutics and Medical Devices
An investment firm and incubator that was established in 2020 and is headquartered in USA has about USD 50 million in assets under management. The firm prefers to participate in early-stage and seed (pre-Series A) financing as well as later-stage and pre-IPO (post-Series B and C) financing while avoiding the middle-stages. The firm manages an evergreen fund with between USD 10 million and USD 20 million of available capital per year. The firm typically makes around 3 or 4 investments per year with typical initial allocation size between USD 2 million and USD 10 million for early-stage companies and around USD 10 million for later-stage companies. The firm utilizes various capital structures as determined on a case- by-case basis and has experience with equity investments and convertible loans. The firm primarily invests in companies based in the United States and China but is open to considering all global opportunities as well.
The firm is primarily interested in investing in companies in the biotechnology therapeutics and medical technology sectors. The firm will consider all modalities across these sectors but has expertise in molecule development and prefers to avoid medical devices. The firm has no experience in digital health but will consider investments in the diagnostics sector but prefers to focus on genomics and biomarker diagnostics. The firm will invest in therapeutics that are pre-clinical or in Phase I to Phase III of clinical trials as well as medical technology and diagnostics that are in development or clinical. The firm is disease agnostic and will consider companies across all indications but has experience investing in cancer and autoimmune related technologies.
The firm prefers to work with experienced management teams are dedicated to their technology and their company. The firm is an active investor and will take a board seat on a case-by-case basis depending on investment size. Plaisance Capital Management will act as both a lead and co-investor.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Canada-Based VC Seeks Global Opportunities in the Field of Precision Medicine, Investing in Therapeutics, Devices, AI/Digital Health, and More
A venture capital firm with offices in Canada was founded by a leading venture capital firm’s former healthcare investment team, who has a successful track record of identifying, building, and growing life science companies. The firm’s newest fund will invest around 80% in Canada-based life science companies and 20% in USA/global companies. The firm will generally participate in Series A financing rounds and beyond, including crossover and IPO; average check sizes will be around $5-10M CAD, with a total of $15-20M CAD will be reserved for follow-on investments. In addition, the firm is also dedicated to company incubation and creation for which the firm will work with earlier stage companies and deploy smaller amounts of capital (around $1M CAD).
The firm has a general theme of investing in precision medicine – technologies that can enhance the quality and accuracy of diagnoses, enable more precise and personalized treatments, targeted therapies such as cell & gene therapy, technologies that leverage AI to accelerate therapeutic development, etc. In terms of sector, the firm seeks to invest 50-60% in therapeutics, 20-30% in medical devices, and 10-15% in AI/digital health/diagnostics. For medical devices, the firm prefers later stage opportunities that are close to commercialization. The firm does not focus on any particular indication area.
The firm does not have specific company or management team requirements. While the firm likes to see management teams with a successful track record and wide range of experiences, this is not required and the firm is open to working on inexperienced management teams. The firm is capable of leading or co-leading investment rounds, and is also open to co-investing with likeminded investors. The firm is very hands-on and leverages their network to actively support the growth of their portfolio companies and provide needed resources.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Investment Firm Allocates Up to $10M in Series A & B Financings of Medical Devices, Diagnostics, and Digital Health Companies Across the Globe
A venture capital firm founded in 2020 and based in the US is seeking opportunities in the medical devices, diagnostics, and digital health sectors of life sciences. The firm is looking to engage in Series A to Series B financing rounds with check sizes between 5 – 10 million USD. The firm prefers to lead the financing rounds but is open to co-investing. The firm will consider opportunities globally.
The firm is interested in early-stage opportunities in medical devices, diagnostics, and digital health sectors but does not invest in therapeutics. The firm is overall opportunistic and will consider various subsectors and indications. For digital health, the firm prefers b-to-b over b-to-c products. The firm will invest in all early-stage companies including pre and post commercial enterprises.
The firm seeks to work with management teams that have prior entrepreneurial experience. The firm prefers to lead financing rounds and will most likely take a board seat when leading. The firm considers themselves an active investor and will work closely with companies.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
